SCPS — Scopus Biopharma Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- -$1.40m
Annual income statement for Scopus Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.686 | 2.69 | 10.2 | 27.6 | 11.7 |
| Operating Profit | -0.686 | -2.69 | -10.2 | -27.6 | -11.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.686 | -2.69 | -10.9 | -27 | -11.7 |
| Net Income After Taxes | -0.686 | -2.69 | -10.9 | -27 | -11.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.686 | -2.69 | -10.9 | -27 | -11.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.686 | -2.69 | -10.9 | -27 | -11.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.047 | -0.185 | -0.811 | -1.09 | -0.55 |
| Dividends per Share |